Robert J. Slack

2.9k total citations · 1 hit paper
80 papers, 1.6k citations indexed

About

Robert J. Slack is a scholar working on Immunology, Molecular Biology and Immunology and Allergy. According to data from OpenAlex, Robert J. Slack has authored 80 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Immunology, 27 papers in Molecular Biology and 21 papers in Immunology and Allergy. Recurrent topics in Robert J. Slack's work include Galectins and Cancer Biology (22 papers), Cell Adhesion Molecules Research (16 papers) and Synthesis and Reactions of Organic Compounds (12 papers). Robert J. Slack is often cited by papers focused on Galectins and Cancer Biology (22 papers), Cell Adhesion Molecules Research (16 papers) and Synthesis and Reactions of Organic Compounds (12 papers). Robert J. Slack collaborates with scholars based in United Kingdom, Sweden and United States. Robert J. Slack's co-authors include Simon J. F. Macdonald, Richard J. D. Hatley, James A. Roper, Gísli Jenkins, Alison C. MacKinnon, K. R. H. Wooldridge, Ross Mills, David A. Hall, Pauline T. Lukey and Alison J. Ford and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Robert J. Slack

77 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emerging therapeutic opportunities for integrin inhibitors

2021 352 citations Robert J. Slack, Simon J. F. Macdonald et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert J. Slack United Kingdom	22	601	486	330	282	275	80	1.6k
Niamh Moran Ireland	25	916 1.5×	301 0.6×	505 1.5×	104 0.4×	331 1.2×	75	2.2k
Fernando Doñate United States	22	897 1.5×	224 0.5×	234 0.7×	109 0.4×	508 1.8×	56	1.8k
Corey P. Causey United States	22	1.1k 1.8×	689 1.4×	372 1.1×	128 0.5×	466 1.7×	37	2.0k
Timothy P. Kogan United States	21	543 0.9×	169 0.3×	274 0.8×	397 1.4×	97 0.4×	38	1.2k
Jun‐ichi Yamashita Japan	23	677 1.1×	145 0.3×	119 0.4×	166 0.6×	421 1.5×	95	1.6k
George A. Heavner United States	18	601 1.0×	438 0.9×	138 0.4×	211 0.7×	118 0.4×	48	1.4k
Chalet Tan United States	26	1.2k 1.9×	317 0.7×	93 0.3×	132 0.5×	351 1.3×	47	2.3k
Krishnakumar Balasubramanian United States	17	780 1.3×	539 1.1×	80 0.2×	42 0.1×	214 0.8×	21	1.7k
Dalia Seger Israel	19	1.5k 2.4×	153 0.3×	132 0.4×	104 0.4×	253 0.9×	24	2.0k
Marco Ponassi Italy	24	765 1.3×	211 0.4×	268 0.8×	228 0.8×	167 0.6×	60	1.5k

Countries citing papers authored by Robert J. Slack

Since Specialization

Citations

This map shows the geographic impact of Robert J. Slack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert J. Slack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert J. Slack more than expected).

Fields of papers citing papers by Robert J. Slack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert J. Slack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert J. Slack. The network helps show where Robert J. Slack may publish in the future.

Co-authorship network of co-authors of Robert J. Slack

This figure shows the co-authorship network connecting the top 25 collaborators of Robert J. Slack. A scholar is included among the top collaborators of Robert J. Slack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert J. Slack. Robert J. Slack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

MacKinnon, Alison C., Duncan C. Humphries, James A. Roper, et al.. (2024). Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver. European Journal of Pharmacology. 985. 177077–177077. 4 indexed citations

Procopiou, Panayiotis A., John W. Barrett, Richard J. D. Hatley, et al.. (2024). Discovery and Development of Highly Potent and Orally Bioavailable Nonpeptidic α_vβ₆ Integrin Inhibitors. Journal of Medicinal Chemistry. 67(19). 17497–17519. 1 indexed citations

Barrett, John W., Glenn A. Burley, Richard J. D. Hatley, et al.. (2024). Core Modifications of GSK3335103 toward Orally Bioavailable α_vβ₆ Inhibitors with Improved Synthetic Tractability. Journal of Medicinal Chemistry. 67(21). 19689–19715. 3 indexed citations

Aslanis, Vassilios, Robert J. Slack, Lise Gravelle, et al.. (2024). Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemotherapy and Pharmacology. 94(5). 707–720. 1 indexed citations

Aparisi, Francisco, Enriqueta Felip, Éric Pichon, et al.. (2023). 1460P GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC). Annals of Oncology. 34. S829–S830. 1 indexed citations

Kim, Henry, Emmanuel Klein, James A. Roper, et al.. (2023). Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonance. SLAS DISCOVERY. 28(5). 233–239. 8 indexed citations

Humphries, Duncan C., Ross Mills, Brian J. McHugh, et al.. (2022). Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation. Frontiers in Pharmacology. 13. 949264–949264. 22 indexed citations

MacKinnon, Alison C., Sanjeev Khindri, Nik Hirani, et al.. (2020). Galactic-1: A Randomized, Double-Blind, Multicentre, Parallel, Placebo-Controlled Phase 2b Study in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered via a Dry Powder Inhaler Over 52 Weeks. A3065–A3065. 5 indexed citations

Onega, Mayca, Christine A. Parker, Christopher Coello, et al.. (2020). Preclinical evaluation of [18F]FB-A20FMDV2 as a selective marker for measuring αVβ6 integrin occupancy using positron emission tomography in rodent lung. European Journal of Nuclear Medicine and Molecular Imaging. 47(4). 958–966. 5 indexed citations

10.

Slack, Robert J., Ross Mills, & Alison C. MacKinnon. (2020). The therapeutic potential of galectin-3 inhibition in fibrotic disease. The International Journal of Biochemistry & Cell Biology. 130. 105881–105881. 95 indexed citations

11.

Barker, Daniel, Panayiotis A. Procopiou, John W. Barrett, et al.. (2019). Profile of a Highly Selective Quaternized Pyrrolidine Betaine α_vβ₆ Integrin Inhibitor—(3S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((1S and 1R,3R)-1-methyl-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-ium-1-yl)butanoate Synthesized by Stereoselective Methylation. Journal of Medicinal Chemistry. 62(16). 7543–7556. 6 indexed citations

12.

Procopiou, Panayiotis A., Niall A. Anderson, John W. Barrett, et al.. (2018). Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic α_vβ₆ Integrin Inhibitor for the Inhaled Treatment of Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry. 61(18). 8417–8443. 31 indexed citations

13.

Procopiou, Panayiotis A., Alison J. Ford, Simon T. Hodgson, et al.. (2017). Design of Phthalazinone Amide Histamine H₁ Receptor Antagonists for Use in Rhinitis. ACS Medicinal Chemistry Letters. 8(5). 577–581. 12 indexed citations

14.

Procopiou, Panayiotis A., Ashley P. Hancock, Simon T. Hodgson, et al.. (2016). The discovery of quinoline based single-ligand human H1 and H3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 26(24). 5855–5859. 6 indexed citations

15.

Shukla, Lena, Laura Ajram, Malcolm Begg, et al.. (2016). 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis. European Journal of Medicinal Chemistry. 115. 14–25. 6 indexed citations

16.

Hall, Eleanor R., et al.. (2016). Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand. Biochemical Pharmacology. 117. 88–96. 20 indexed citations

17.

Ajram, Laura, Malcolm Begg, Robert J. Slack, et al.. (2014). Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonists. European Journal of Pharmacology. 729. 75–85. 40 indexed citations

18.

Salmon, M, Mark A. Luttmann, James J. Foley, et al.. (2013). Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases. Journal of Pharmacology and Experimental Therapeutics. 345(2). 260–270. 64 indexed citations

19.

Slack, Robert J. & David A. Hall. (2012). Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC chemokine receptor CCR4. British Journal of Pharmacology. 166(6). 1774–1792. 35 indexed citations

20.

Slack, Robert J., et al.. (2011). In vitro characterisation of the duration of action of the histamine-1 receptor antagonist azelastine. European Journal of Pharmacology. 670(2-3). 586–592. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact